RNAC Q4 2023 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$218M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M-50.8% YoY

Gross Profit

$8M100.0% margin

Operating Income

-$36M-439.5% margin

Net Income

-$178M-2149.3% margin

EPS (Diluted)

$-41.56

QoQ Revenue Growth

+26.2%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$305M

Total Liabilities

$745M

Stockholders' Equity

-$440M

Cash & Equivalents

$77M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$17M	-50.8%
Gross Profit	$8M	$16M	-48.9%
Operating Income	-$36M	-$8M	-327.6%
Net Income	-$178M	$6M	-3114.7%